Australia markets close in 6 hours 9 minutes

Aclaris Therapeutics, Inc. (8AT.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
1.1065-0.0845 (-7.09%)
At close: 08:00AM CEST
Full screen
Previous close1.1015
Open1.1065
Bid0.0000 x 0
Ask0.0000 x 0
Day's range1.1065 - 1.1065
52-week range0.5900 - 11.8450
Volume2,820
Avg. volume59
Market cap78.855M
Beta (5Y monthly)0.24
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update

    - Progressing ATI-2138 into Atopic Dermatitis -- Management to Host Conference Call at 5:00 PM ET Today - WAYNE, Pa., May 07, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the first quarter of 2024 and provided a corporate update. “We are pleased to announce that following a review of the potential development pat

  • GlobeNewswire

    Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update

    WAYNE, Pa., April 30, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced it will report financial results for the first quarter 2024 on Tuesday, May 7, 2024, after the closing of the U.S. financial markets. Management will conduct a conference call at 5:00 p.m. ET on the same day to provide a corporate update. The conference call will be webcas

  • PR Newswire

    Flare Therapeutics Appoints Douglas Manion, M.D., FRCP (C) as Chief Executive Officer

    Flare Therapeutics Inc., a clinical-stage biotechnology company targeting transcription factors to discover precision medicines for cancer and other diseases, today announced the appointment of Douglas Manion, M.D., FRCP (C), as Chief Executive Officer, effective immediately. Dr. Manion brings over two decades of experience in pharmaceutical research and development, having held leadership roles across several biotechnology and pharmaceutical companies. He succeeds interim CEO Abbie Celniker, Ph